Literature DB >> 25066707

Comorbidities of pediatric systemic lupus erythematosus: A 6-year nationwide population-based study.

Pei-Chun Chan1, Chong-Hua Yu2, Kuo-Wei Yeh1, Jorng-Tzong Horng3, Jing-Long Huang4.   

Abstract

OBJECTIVE: Systemic lupus erythematous (SLE) is a systemic and complex disease that can involve multiple organs. To clarify the risk of developing associated comorbidities after a diagnosis of SLE in children, we used the National Health Insurance Research Database (NHIRD) in Taiwan to investigate diseases experienced in these patients. This is the first nationwide population-based study of the comorbidities of pediatric SLE patients.
METHODS: The study was based on data from the NHIRD in Taiwan. Children were enrolled who were below the age of 18 years and whose disease corresponded to the International Classification of Disease, Ninth Revision Clinical Modification (ICD-9-CM) diagnostic code of 710.0 (SLE). The comorbidities associated with SLE were defined by the ICD-9-CM codes of diseases that presented after the SLE diagnosis. We analyzed the common diseases in SLE patients and compared the frequency of these diseases between pediatric SLE patients and the non-SLE population.
RESULTS: From January 1, 2003 to December 31, 2008, we enrolled 904 SLE patients (774 females, 130 males). Infection (86.36%) was the most common comorbidity in pediatric SLE. Other comorbidities were musculoskeletal diseases (16.7%), cardiovascular diseases (16.37%), ocular diseases (10.73%), and renal diseases (6.75%). Children with SLE had a higher risk of heart failure, hypertension, osteoporosis, cataracts, glaucoma, dyslipidemia, seizures, encephalopathy, and malignant changes, compared to non-SLE populations.
CONCLUSION: The population-based cohort demonstrated several systemic and/or chronic diseases in pediatric SLE patients in Taiwan. Children with SLE were more susceptible to these diseases, including malignancy, compared to the non-SLE population.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Comorbidity; Pediatric; Systemic lupus erythematosus; Taiwan

Mesh:

Year:  2014        PMID: 25066707     DOI: 10.1016/j.jmii.2014.05.001

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  4 in total

1.  Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011.

Authors:  Louisa B Goss; Justin R Ortiz; Daryl M Okamura; Kristen Hayward; Christopher H Goss
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

2.  Risks of ophthalmic disorders in patients with systemic lupus erythematosus - a secondary cohort analysis of population-based claims data.

Authors:  Chun-Shuo Hsu; Chia-Wen Hsu; Ming-Chi Lu; Malcolm Koo
Journal:  BMC Ophthalmol       Date:  2020-03-11       Impact factor: 2.209

Review 3.  Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.

Authors:  Wei Sun; Pengchong Li; Jianping Cai; Jie Ma; Xuan Zhang; Yong Song; Yudong Liu
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

4.  Association of systemic lupus erythematosus disease activity index score with clinical and laboratory parameters in pediatric onset systemic lupus erythematosus.

Authors:  Roshila Shamim; Sumaira Farman; Shabnam Batool; Saira Elaine Anwer Khan; Muhammad Kamil Hussain Raja
Journal:  Pak J Med Sci       Date:  2020 Mar-Apr       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.